Product and Geographic Information

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Product and Geographic Information

Product and Geographic Information

The Company’s operations include the following product portfolios, which constitute one operating segment engaged in developing and delivering innovative health solutions through its portfolio of prescription therapies within women’s health, biosimilars and established brands.

Revenues of the Company’s products were as follows:

	Three Months Ended September 30,												Nine Months Ended September 30,
	2022						2021						2022						2021
($ in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total
Women’s Health
Nexplanon/Implanon NXT	$	151	$	78	$	229	$	120	$	55	$	175	$	401	$	194	$	595	$	389	$	154	$	543
Follistim AQ	27		33		60		29		32		61		79		100		179		81		97		178
NuvaRing	27		23		50		21		28		49		65		68		133		68		79		147
Ganirelix Acetate Injection	6		30		36		5		20		25		20		77		97		19		66		85
Cerazette	—		15		15		—		18		18		—		47		47		—		53		53
Other Women's Health (1)	24		39		63		18		35		53		80		108		188		80		111		191
Biosimilars
Renflexis	54		7		60		48		6		54		145		20		166		119		17		136
Ontruzant	15		14		29		9		47		56		35		52		87		20		81		101
Brenzys	—		24		24		—		14		14		—		52		52		—		35		35
Aybintio	—		10		10		—		10		10		—		29		29		—		26		26
Hadlima	—		6		6		—		5		5		—		14		14		—		9		9
Established Brands
Cardiovascular
Zetia	2		85		87		1		90		91		7		280		287		6		276		282
Vytorin	1		30		31		3		38		41		6		98		104		8		119		127
Atozet	—		109		109		—		114		114		—		350		350		—		347		347
Rosuzet	—		17		17		—		15		15		—		55		55		—		48		48
Cozaar/Hyzaar	2		68		70		3		84		87		11		244		256		9		256		265
Other Cardiovascular (1)	1		34		35		1		48		49		3		117		120		3		145		148
Respiratory
Singulair	3		92		94		2		98		100		8		308		316		10		289		300
Nasonex	—		49		49		—		49		48		9		173		182		3		141		144
Dulera	31		9		40		48		8		56		98		30		127		121		25		146
Clarinex	—		25		26		2		27		28		3		96		99		5		78		83
Other Respiratory (1)	11		10		21		14		5		18		34		32		66		43		20		64
Non-Opioid Pain, Bone and Dermatology
Arcoxia	—		64		64		—		65		65		—		185		185		—		184		184
Fosamax	1		35		36		1		45		46		2		115		117		3		130		132
Diprospan	—		28		28		—		34		34		—		91		91		—		92		92
Other Non-Opioid Pain, Bone and Dermatology (1)	2		63		65		9		69		79		10		200		210		12		201		213
Other
Proscar	—		26		27		—		27		27		1		76		77		1		91		92
Propecia	2		28		30		1		33		34		5		90		95		5		96		101
Other (1)	6		81		87		10		83		95		21		230		251		32		230		262
Other (2)	—		39		39		1		51		52		—		115		116		(2)		171		168
Revenues	$	366	$	1,171	$	1,537	$	346	$	1,254	$	1,600	$	1,043	$	3,646	$	4,689	$	1,035	$	3,666	$	4,701

Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health.

(2) Includes manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation.

Revenues by geographic area where derived are as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Europe and Canada	$	363	$	410	$	1,243	$	1,314
United States	366		346		1,043		1,035
Asia Pacific and Japan	283		287		888		874
China	241		252		721		693
Latin America, Middle East, Russia and Africa	236		238		665		595
Other (1)	48		67		129		190
Revenues	$	1,537	$	1,600	$	4,689	$	4,701

(1) Primarily reflects manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation.